GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » ABL Diagnostics (XPAR:ABLD) » Definitions » EV-to-FCF

ABL Diagnostics (XPAR:ABLD) EV-to-FCF : -271.27 (As of Jun. 01, 2024)


View and export this data going back to 1989. Start your Free Trial

What is ABL Diagnostics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, ABL Diagnostics's Enterprise Value is €50.46 Mil. ABL Diagnostics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.19 Mil. Therefore, ABL Diagnostics's EV-to-FCF for today is -271.27.

The historical rank and industry rank for ABL Diagnostics's EV-to-FCF or its related term are showing as below:

XPAR:ABLD' s EV-to-FCF Range Over the Past 10 Years
Min: -271.27   Med: 1.29   Max: 17.14
Current: -271.27

During the past 13 years, the highest EV-to-FCF of ABL Diagnostics was 17.14. The lowest was -271.27. And the median was 1.29.

XPAR:ABLD's EV-to-FCF is ranked worse than
100% of 360 companies
in the Healthcare Providers & Services industry
Industry Median: 19.13 vs XPAR:ABLD: -271.27

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-01), ABL Diagnostics's stock price is €3.04. ABL Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €0.047. Therefore, ABL Diagnostics's PE Ratio for today is 64.68.


ABL Diagnostics EV-to-FCF Historical Data

The historical data trend for ABL Diagnostics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABL Diagnostics EV-to-FCF Chart

ABL Diagnostics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.47 -3.80 20.02 -22.54 -

ABL Diagnostics Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -22.54 - - -

Competitive Comparison of ABL Diagnostics's EV-to-FCF

For the Health Information Services subindustry, ABL Diagnostics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ABL Diagnostics's EV-to-FCF Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where ABL Diagnostics's EV-to-FCF falls into.



ABL Diagnostics EV-to-FCF Calculation

ABL Diagnostics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=50.456/-0.186
=-271.27

ABL Diagnostics's current Enterprise Value is €50.46 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ABL Diagnostics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.19 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ABL Diagnostics  (XPAR:ABLD) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

ABL Diagnostics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.04/0.047
=64.68

ABL Diagnostics's share price for today is €3.04.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ABL Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €0.047.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


ABL Diagnostics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of ABL Diagnostics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


ABL Diagnostics (XPAR:ABLD) Business Description

Traded in Other Exchanges
N/A
Address
72c, rue de, WOIPPY, Thionville, FRA, 57140
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.

ABL Diagnostics (XPAR:ABLD) Headlines

No Headlines